Introduction {#sec1}
============

Grade IV astrocytoma or glioblastoma multiforme (GBM) is a kind of tumor that stems from glial (supportive cells) tissue of the brain and spinal cord in the CNS (central nervous system) and contains cells that grow fast and look very different in comparison with normal cells. This cancer is more common in adults than children and affects the brain more often than the spinal cord.[@bib1] The median survival for GBM patients is less than 15--20 months.[@bib2] The incidence of GBM in European and US populations is less than 2 and about 3 per 100,000, respectively, per year, and it tends to be higher in more developed countries. It is 1.5-fold more common in men.[@bib3]

Numerous factors contribute to a tragic outcome for GBM patients. (1) Surgery and radiation therapy have limitations because of the proximity of critical functional structures in the brain. (2) The tumor margin is hardly defined, since cancerous cells tend to be highly invasive, and they migrate into the brain parenchyma and through blood vessels and white matter tracks. Therefore, recurrence typically occurs within a few centimeters. (3) The existence of cancer stem cells (CSCs) that are tumor initiating and propagating, and in some cases radiotherapy and chemotherapy resistant, provides the chance of recurrence. (4) Targeting specific oncogenic pathways because of heterogeneous genotype, histology, and pathology is complex. (5) The blood-brain barrier (BBB) limits therapeutic delivery. (6) The immune-privileged status of the brain and immune-suppressive features of the tumor limit systemic immune responses. As a result, there is an essential need for new therapeutic strategies that can overcome these barriers to treatment, and gene therapy may hold promise for the treatment of GBM.[@bib4] The most common strategies to treat GBM via gene therapy include suicide gene therapy, immune response activation, oncolytic viruses, and reprogramming.[@bib5]

Advances in the understanding of signaling pathways that underlie glioblastoma pathogenesis have resulted in the development of new therapeutic approaches targeting multiple oncogenic signaling aberrations associated with GBM. The signaling pathways that are physiologically and pathologically relevant to GBM consist of p53, retinoblastoma (RB), phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/Akt/mammalian target of rapamycin (mTOR), RAS/mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription 3 (STAT3)/ZIP4.[@bib6] Based on The Cancer Genome Atlas (TCGA) research, the RB signaling pathway was altered in 78% of glioblastoma samples, consisting of 52% mutation or homozygous deletion of *CDKN2A* (P16/INK4A), 47% homozygous deletion of *CDKN2B*, 2% homozygous deletion of *CDKN2C*, and amplification of *CDK4* and *CDK6* to 18% and 1%, respectively.[@bib7]^,^[@bib8] The tumor suppressor RB (pRB) has a crucial role in inhibiting cell cycle progression by binding and inhibiting E2F family transcription factors. In brief, in the G~1~ phase, pRB is normally inactivated by Cyclin D/CDK4/CDK6-induced phosphorylation, which leads to the release of pRB from E2F and the subsequent stimulation of cell progression into the S phase. *CDKN2B*, which is a *CDK* inhibitor, forms a complex with *CDK4* or *CDK6*, thereby preventing the activation of *CDKs*. The downstream effect of this inhibition is preventing cell growth and the cell cycle through G~1~ progression, by maintaining the activation state of pRB. Amplification of *CDK4* and *CDK6* in glioblastomas is common, and they both play pivotal roles in astrocytic tumorigenesis and glioma progression. Since the pRB pathway is inactivated by the kinase activity of the CDK4/CDK6/Cyclin D complex, inhibition of *CDK4* and *CDK6* may be a chemotherapeutic treatment strategy in GBM patients with aberrantly expressed pRB.[@bib6] Amplification of both or either *CDK4* or *CDK6* could be one of the important events that provide a growth advantage to astrocytic tumor.[@bib9]

In addition, TCGA research reveals that the p53 signaling pathway was altered in 87% of glioblastoma samples and consisted of 49% mutation or homozygous deletion of *CDKN2A* (ARF), 35% homozygous deletion or mutation of *TP53*, and amplification of *MDM2* and *MDM4* to 14% and 7%, respectively.[@bib10]^,^[@bib11] MDM2 is an E3 ubiquitin ligase and important negative regulator of the p53 tumor suppressor. It negatively regulates p53 in two ways: direct binding and transcriptional inhibition, and degradation through its E3 ligase activity.[@bib12] Amplification of *MDM2* only occurred in tumors without a p53 mutation, suggesting that *MDM2* overexpression may provide alternative means for tumors to inactivate p53-regulated growth control without having to alter p53 itself.[@bib13]

MicroRNAs (miRNAs) are single-stranded RNAs (ssRNAs) of ∼22 nt in length, and they are generated from endogenous hairpin-shaped transcripts. miRNA molecules play a guiding role in post-transcriptional gene regulation by base pairing with the target mRNAs, usually in the 3′ UTR (untranslated region). miRNA and target mRNA binding typically leads to translational repression and exonucleolytic mRNA decay, although highly complementary targets can be cleaved endonucleolytically. Other types of regulation, such as translational activation and heterochromatin formation, have also been described. It is predicated that more than one-third of human genes are directly targeted by miRNAs, and the unique combination of miRNAs in each cell type determines the use of thousands of mRNAs.[@bib14] Precise control of miRNA levels is crucial to maintain normal cellular functions, and there is a relationship between deregulated miRNAs and a variety of cancers, such as glioblastoma and medulloblastoma.[@bib15] There is some evidence that implicates miRNAs as having a role in the control of cyclin expression and, consequently, cell cycle progression. For instance, let-7 regulates cyclin D2, and it is poorly expressed in lung tumors and lung cancer cell lines.[@bib16] For another example, miR-122 was downregulated in hepatic tumors. Gramantieri et al.[@bib17] showed that miR-122a downregulates cyclin G1 expression in a hepatocellular carcinoma (HCC)-derived cell line.

Taking all of these examples into account, miRNA-mediated suppression of upregulated genes that are involved in cell cycle signaling and progression seems a promising strategy to inhibit the proliferation and invasiveness of cancer cells. In our study, we chose miR-129, which targets *CDK4*, *CDK6*, and *MDM2* genes based on bioinformatics databases, and it potentially can inhibit cancer proliferation. The goal of our study was to investigate the effect of overexpression of miR-129 on the expression of *CDK4*, *MDM2*, and *CDK6* in glioma cells and provide proof of a relationship between miR-129 and *CDK4*/*CDK6/MDM2* expression.

Results {#sec2}
=======

miRNA and Gene Selection {#sec2.1}
------------------------

According to the KEGG database and published documents, *CKD4*, *CKD6*, and *MDM2* were selected as upregulated genes that play a role in RB and p53 signaling pathways. Based on the Expression Atlas, the expression of *CDK4* in U-251 and U-87 cell lines is medium (142 TPM \[transcripts per million\] and 218 TPM, respectively). Additionally, the expression of *CDK6* is medium in both of the cell lines (77 TPM for U251 and 18 TPM for U87), and the expression of *MDM2* is medium (23 TPM for U251 and 26 TPM for U87). Thus, we were able to inhibit RB and p53 signaling pathways in glioblastoma via downregulation of these genes in these cell lines. Afterward, we used TargetScan, RNA22, and miRanda algorithms to choose miRNAs that can potentially target desirable genes. A candidate miRNA, hsa-miR-129-5p, was selected according to the table score ([Table 1](#tbl1){ref-type="table"}).Table 1miR-129-5p Binding Sites of *CDK4*, *CDK6*, and *MDM2* 3′ UTRs Predicted by Bioinformatics DatabasesTargetScanmiRandaRNA22Seed of miR-129-5pSite TypeContex++ ScoremirSVR ScoreFolding Energy (kcal/mol)![](fx1.gif)poorly conserved 7-mer-1A−0.06\-\-\--−11.30![](fx2.gif)poorly conserved 7-mer-m8−0.17−0.0049−13.70![](fx3.gif)poorly conserved 7-mer-1A−0.02−0.0021−16.20

Induction of miR-129 Expression in Glioblastoma Cells {#sec2.2}
-----------------------------------------------------

Lentiviral particles that contain miR-129 (LV-miR-129) were used for transduction of glioblastoma cell lines U251 ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and U87 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Consequently, the expression level of miR-129 in U251 and U87 cell lines was quantified via real-time PCR. The results show that the miR-129 expression increased to 10.08- and 1,533.99-fold (p \< 0.0001) in U251 and U87 cells, respectively, in comparison with the control group ([Figures 1](#fig1){ref-type="fig"}A and 1B).Figure 1Upregulation of miR-129 in GBM Cells Can Affect Genes\' Expression(A and B) Upregulation of miR-129 in (A) U251 and (B) U87 cells compared with the control group. (C) Downregulation of *CDK4*, *CDK6*, and *MDM2* in transduced cells with LV-miR-129 compared with the control group. \*p \< 0.05, \*\*\*\*p \< 0.0001. SC, scrambled control.

Expression of *CDK4*, *CDK6*, and *MDM2* in Glioblastoma Cell Lines {#sec2.3}
-------------------------------------------------------------------

Following the proof of significant overexpression of miR-129 in transduced cell lines, the expressions of *CDK4*, *CDK6*, and *MDM2* genes were analyzed by real-time PCR. We analyzed the total mRNA of these cells and determined that expression of *CDK4* in U251 and U87 cell lines declined by 69.8% and 47% (p \< 0.05), respectively, and expression of *CDK6* and *MDM2* in U251 cells decreased by 55.3% (p \< 0.0001) and 34.7% (p \< 0.05), respectively ([Figure 1](#fig1){ref-type="fig"}C). Our bioinformatics studies suggested that miR-129 targets these genes and may proceed to inhibit cell signaling. Hence, the real-time PCR data suggested that the prediction could be trustworthy.

miR-129 Targets *CDK4*, *CDK6*, and *MDM2* Dramatically {#sec2.4}
-------------------------------------------------------

A luciferase reporter assay was taken into account to prove the significant interaction between miR-129 and the predicted binding site in the 3′ UTR of the understudied genes. The results indicated that overexpression of miR-129 can decrease the expression of the *CDK4* gene by 58.9% (p \< 0.01) and reduce the *CDK6* expression by 35.7% (p \< 0.0001) in HEK293 cells. The MDM2 expression was reduced by 49% (p \< 0.001) as well ([Figure 2](#fig2){ref-type="fig"}). As a result, we can claim that miR-129 significantly targets and inhibits *CDK4*, *CDK6*, and *MDM2* expression significantly.Figure 2*CDK4*, *CDK6*, and *MDM2* Are Targeted by miR-129Analysis of luciferase assay in HEK293 cells co-transfected with miR-129 and *CDK4*-3′ UTR or *CDK6*-3′ UTR, or *MDM2*-3′ UTR in comparison with control groups that are HEK293 cells co-transfected with scramble control and 3′ UTR vectors. \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. SC, scrambled control. n = 3.

Overexpression of miR-129 Inhibits Cell Cycle and Growth in Glioblastoma Cells {#sec2.5}
------------------------------------------------------------------------------

To investigate whether miR-129 affects glioblastoma cell growth via regulation of *CDK4*, *MDM2*, and *CDK6*, we performed a cell cycle analysis. First, we transduced the glioblastoma cells with LV-miR-129 and then analyzed the cell cycle by the flow cytometry method. We found that miR-129 arrests U87 cells in pre-G~2~ phase, and the population of cells in the G~2~ phase decreased significantly to 10% (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}; [Figure S2](#mmc1){ref-type="supplementary-material"}). Cell cycle analysis of U251 cells showed no significant changes after miR-129 overexpression.Figure 3Flow Cytometry Analysis of Cell CycleThe pre-G~2~ arrest of U87 cell line after overexpression of miR-129 compared with U87 cells transduced with scramble control. \*p \< 0.05. SC, scrambled control. n = 3.

The wound healing assay results demonstrated that miR-129-5p-transduced cells had a significantly lower wound closure rate than that of the control group ([Figure 4](#fig4){ref-type="fig"}). Inhibition of the U87 cell line was so strong that we could not expand U87-transduced cells for this assay, although we cultured them for more than 2 weeks. These results suggested that overexpression of miR-129 correlated with inhibition of cell cycle progression in glioblastoma cells, and that miR-129 may serve as a tumor suppressor in glioma.Figure 4U251 Transduced Cells by LV-miR-129 Demonstrated a Lower Wound Closure Rate Than Did the Control Group\*p \< 0.05. n = 3.

Discussion {#sec3}
==========

Glioblastoma is one of the most lethal forms of human cancer. Despite improvements in understanding GBM molecular mechanisms, certain treatments are not available and require further studies. Previously, it was shown that miR-129 is downregulated in human glioma cancer.[@bib18] miRNAs play roles in almost all biological pathways, such as cell proliferation, apoptosis, and tumorigenesis. Dysregulation of miRNAs can lead to different kinds of diseases, such as cancer. They have the potential of being tumorigenic or tumor suppressive at the beginning of cancer and affect its progression, metastasis, and response to treatment.[@bib19]

Previously, it was shown that extrinsic miR-129 expression functions as a tumor suppressor in colon[@bib20] and papillary thyroid cancer.[@bib21] Additionally, some targets and functions have been recognized for miR-129 through its induced overexpression in glioma cell lines. In brief, in 2017 it was shown that miR-129-5p could target *FNDC3B* by binding to the 3′ UTR. The overexpression of miR-129-5p and the inhibition of *FNDC3B* can both inhibit U87 cell viability, proliferation, migration, and invasion while promoting cell apoptosis.[@bib22] Xiong et al.[@bib23] indicated that miR-129 inhibits the expression of *SOX2* and suppresses glioma stem cell proliferation. Alternatively, MALAT1 as a long non-coding RNA (lncRNA) promotes the expression of *SOX2* and boosts the viability and proliferation of glioma stem cells. The effects of MALAT1 and miR-129 on the glioma tumor in a xenograft mouse model indicated that MALAT1 promotes glioma tumor growth by regulating miR-129 and *SOX2*. In another study, it has been shown that miR-129-2 is downregulated in human glioma cancer, partially due to its DNA promoter hypermethylation. Overexpression of miR-129-2 suppressed cell growth, migration, and invasion and promoted cell apoptosis in U373 and U87 glioma cell lines through targeting the oncogene *HMGB1* (high-mobility group box 1), which has been found to be upregulated and involved in the pathogenesis of many kinds of human cancers, and inhibiting its expression in glioma cells.[@bib18] Moreover, it has been shown that miR-129 is a new inducer of autophagy both through mTOR signaling and upregulation of *Beclin-1* by targetedly suppressing Notch-1 in U251 and U87 cells. In fact, miR-129-5p triggered autophagy partially by the Notch-1/*E2F7*/*Beclin*-1 axis.[@bib24]

In our study, two cell lines were used to compare the results in different mutation patterns and to confirm the reproducibility of our tests. Both U251 and U87 cell lines are mutant in the PTEN gene and have a methylated MGMT promoter, while the p53 gene is mutant in the U251 cell line as well.[@bib25] The present study indicated that induced expression of miR-129 negatively correlated with expression of *CKD4*, *CDK6*, and *MDM2* in real-time PCR. To confirm the significant correlation between miR-129 and genes, a luciferase assay was used. Analysis of assays demonstrated that miR-129 dramatically targets the 3′ UTR of *CDK4*, *CDK6*, and *MDM2*. Targeted genes have function in RB and p53 signaling pathways and are upregulated in glioma. Therefore, their suppression via miR-129 can potentially inhibit cell signaling and promote cell cycle arrest. As we expected, cell cycle analysis verified pre-G~2~ arrest, and wound healing assays showed significant proliferation inhibition in comparison with the control group.

Conclusion {#sec4}
==========

In summary, the findings of the present study identified *CDK4*, *CDK6*, and *MDM2* as new targets of miR-129 in glioma cells, and these new findings can be of help in future clinical and GBM signaling-based research.

Materials and Methods {#sec5}
=====================

Bioinformatics Analysis {#sec5.1}
-----------------------

The KEGG database was used to investigate signaling pathways, and upregulated genes were identified via published documents based on TCGA project. Additionally, the high-throughput data from the Expression Atlas database was used to assess the expression of genes in glioma cell lines. To select miRNAs that target desirable upregulated genes, we used the following bioinformatics databases: TargetScan with a context++ score lower than −0.01, RNA22 with maximum folding energy for a heteroduplex of −10 kcal/mol, and the miRanda algorithm with a mirSVR score lower than −0.001 thresholds.

Cell Lines and Culture {#sec5.2}
----------------------

Studied cell lines consisted of U87MG (IBRC C10982) and HEK293 cells (IBRC C10139), which were purchased from the Iranian Biological Resource Center (IBRC, Tehran, Iran). U251 was gifted from the Stem Cell Technology Research Center (Tehran, Iran), and short tandem repeat (STR) DNA profiling analysis verified cell authentication. All of the cell lines were cultured in high-glucose DMEM (4.5 g/L) (Bio Idea, Tehran, Iran) supplemented with 10% fetal bovine serum (FBS) (Gibco) and antibiotics (100 U/mL penicillin,100 mg/mL streptomycin) in a 5% CO~2~ incubator at 37°C. All cells were passaged at 2- or 3-day intervals.

Cloning of Genes and miRNA {#sec5.3}
--------------------------

The mir-129 gene was amplified by PCR using Taq DNA polymerase (cinnaGen) and specific primers ([Table S1](#mmc1){ref-type="supplementary-material"}). Then, it was cloned into a pCDH-CMV-MCS-EF1-cGFP-T2A-puro vector (System Biosciences, USA). The full-length 3′ UTR of the *CDK4* gene (1,060th nt to the end of mRNA NM_000075.4) and partial lengths of *CDK6* 3′ UTR (6,998--11,580 nt of transcript variant 1 mRNA NM_001259.8) and *MDM2* 3′ UTR (1,593--6,048 nt of transcript variant 3 mRNA NM_001145337.3) were amplified by PCR on genomic DNA using Takara SpeedSTAR HS DNA polymerase (catalog no. RR070A/B) and specific primers ([Table S1](#mmc1){ref-type="supplementary-material"}). PCR fragments were cloned into the psiCHECK-2 Dual-Luciferase reporter plasmid separately (Promega, Madison, WI, USA) downstream of the Renilla luciferase gene. The pLenti-III-eGFP scramble vector was used as a negative control for miRNA.

RNA Isolation and Quantitative Real-Time RT-PCR {#sec5.4}
-----------------------------------------------

Total RNA was extracted from transduced glioma cell lines after 72 h using a GeneAll Hybrid-R kit (catalog no. 305-101), according to the manufacturer's instructions. The quality and concentration of total RNA were examined using spectrophotometry. Extracted total RNA was converted to cDNA by using Moloney murine leukemia virus (M-MLV) reverse transcription (RT) enzyme (Thermo Fisher, catalog no. 28025013) and a specific RT primer for miR-129 and random hexamer for *CDK4*, *CDK6*, and *MDM2* expression.

For qPCR, miR-129 expression was quantitated by using specific primers and a TaqMan probe relative to *SNORD47* as an endogenous control. The *CDK4*, *CDK6*, and *MDM2* genes' expressions were calculated relative to the *β2M* gene using SYBR Green. The primers in this study used for cDNA synthesis and real-time PCR are as shown in [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Relative expression was determined using the 2^−ΔΔCt^ method.

Virus Production {#sec5.5}
----------------

Recombinant lentiviruses were produced by transfection of one T25 flask of HEK293 cells at 60%--80% confluency with 2 μg of lentiviral vector (carrying hsa-miR-129), 2 μg of psPAX2 (gag/pol), and 1 μg of pMD2.G (VSVg) using the QIAGEN PolyFect transfection reagent (QIAGEN, Hilden, Germany, catalog no. 301107). psPAX2 and pMD2.G virus packaging helper vectors were purchased from the Stem Cell Technology Research Center (Tehran, Iran). Virus supernatant was collected in the 3 following days. For *in vitro* assays, glioblastoma cell lines were cultured in a T25 flask at 60%--80% confluency and were transduced by using hexadimethrine bromide (also known as Polybrene) as a transduction enhancer.

Luciferase Reporter Assay {#sec5.6}
-------------------------

In brief, for the luciferase reporter assay, miR-129 or scramble vector was transfected into cells, along with *CDK4*-3′ UTR, *CDK6*-3′ UTR, or *MDM2*-3′ UTR, using Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer's protocol. Luciferase activity was evaluated 48 h after transfection using a Dual-Luciferase reporter assay system (Promega), according to the manufacturer's instructions. Firefly luciferase activity was used for normalization.

Flow Cytometry Analysis {#sec5.7}
-----------------------

Cell cycle was evaluated 72 h after transduction. Transduced cells were trypsinized and washed in ice-cold PBS. Afterward, cells were fixed with cold paraformaldehyde for 1 h at 4°C. Then, we permeabilized cells by adding 70% ethanol at −20°C drop-wise to the cell pellet with the tube sitting on the vortex mixer and incubated the cell suspension overnight at −20°C. Subsequently, we stained cells with propidium iodide (PI) working solution, which consisted of PI, PBS, Triton X-100, and RNase A, and incubated them at 37°C in the dark for 30 min. Then, we analyzed the samples on a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).

Statistical Analysis {#sec5.8}
--------------------

The data in this study are presented as mean ± SD. Data were compared using Student's t test with GraphPad Prism 6.0 software. Real-time data were statistically analyzed by REST 2009 software, which is under QIAGEN supervision. Differences at p ≤ 0.05 were considered significant.

Wound-Healing Assay {#sec5.9}
-------------------

Cell migration was analyzed using a wound-healing assay. Briefly, miR-129 or non-transduced cells were cultured to 80% confluency in 24-well plates. Then, an artificial wound was made, after which the cells were further incubated (0 h). Migration to the scratched area was imaged at 6 and 24 h after wounding. The wound closure was measured by ImageJ software relative to the total area of wounding.

Author Contributions {#sec6}
====================

The study was conceptualized by E.A.; The methodology was given by E.A. and M.S.; A.M. carried out the experiments and analyzed the data. R.R.V. and S.G. contributed to designing microRNA and luciferase vectors constructs and assisted with gene cloning. F.J.A. assisted with lentiviral vector packaging and manipulation. The manuscript is written by A.M. and edited by E.A.

Supplemental Information {#appsec2}
========================

Document S1. Figures S1 and S2 and Tables S1--S3Document S2. Article plus Supplemental Information

The authors would like to thank the National Institute for Medical Research Development (NIMAD) for the financial support of this research (grant 942974).

Supplemental Information can be found online at <https://doi.org/10.1016/j.omtn.2019.11.033>.
